Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002237 | A Study of Peldesine (BCX-34) in HIV-Infected Patients | PHASE1 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Peldesine | DRUG | - |
Inclusion Criteria Patients must have: * Documented HIV infection. * CD4 cell count greater than or equal to 300 cells/mm3 on 3 occasions prior to protocol treatment. * Plasma viral load by Roche Amplicor HIV Monitor assay greater than or equal to 2,000 RNA copies/ml and less than or equal to 50,0...